In conclusion, elucidating different mechanisms in migration and invasion as well as the potential of SOX2 re-expression to reverse the mesenchymal subtype into a more proneural subtype, should thus open a strategy to alternative treatments in glioblastoma. This evidence concerns the gene SOX2 and glioblastoma.